Latest / AI Investment Edge: Stocks, Markets & Money / Boston Scientific: Small Devices, Big Expectations | EP025
Transcript
- 0:00SPEAKER_00: You know,
- 0:00SPEAKER_00: usually when we talk about medical diagnosis,
- 0:02SPEAKER_00: there's this expectation of mechanical precision, right?
- 0:07SPEAKER_00: You break your arm, the x-ray shows that jagged white line and the doctor just points at it.
- 0:12SPEAKER_00: It's broken or it's not.
- 0:13SPEAKER_01: Right.
- 0:13SPEAKER_01: Yeah.
- 0:14SPEAKER_01: It's a clean, visible categorization.
- 0:17SPEAKER_01: It provides a sense of comfort, honestly.
- 0:21SPEAKER_01: We naturally gravitate towards systems where the problem and
- 0:24SPEAKER_01: the solution are just immediately apparent.
- 0:27SPEAKER_00: Exactly.
- 0:28SPEAKER_00: But then you step into the actual business of healthcare,
- 0:31SPEAKER_00: specifically like the world of medical devices and capital allocation,
- 0:35SPEAKER_00: and suddenly that x-ray machine is just malfunctioning.
- 0:38SPEAKER_01: Oh, completely.
- 0:39SPEAKER_00: We are looking at a financial landscape today that is genuinely murky.
- 0:44SPEAKER_00: Small devices, big expectations.
- 0:47SPEAKER_00: Because the central question for this deep dive is
- 0:49SPEAKER_00: whether Boston Scientific can actually translate broad demand for medical procedures
- 0:54SPEAKER_00: into tangible cash.
- 0:56SPEAKER_01: And, you know,
- 0:57SPEAKER_01: they have to do this while battling fierce competition,
- 1:00SPEAKER_01: making these massive internal investments and pursuing huge pending acquisitions.
- 1:06SPEAKER_00: Right.
- 1:07SPEAKER_00: So welcome to episode 25 of AI Investment Edge.
- 1:10SPEAKER_01: It's the absolute definition of diagnostic muddy waters.
- 1:14SPEAKER_01: And to navigate it,
- 1:15SPEAKER_01: we are analyzing the September iPulse AI Research View for Boston Scientific.
- 1:20SPEAKER_00: So what's the headline for the listener today?
- 1:22SPEAKER_01: The headline here is that the actual released September model assigned a strong buy
- 1:27SPEAKER_01: for both the one year and five year horizons.
- 1:30SPEAKER_01: And those have fixed endpoints of September 18th, 2027 and September 18th, 2031.
- 1:36SPEAKER_01: I'll only state those specific dates once, but they anchor everything.
- 1:39SPEAKER_00: OK, but before we go any further, let's just establish some ground rules here.
- 1:43SPEAKER_00: We are looking strictly at the original September research basis.
- 1:46SPEAKER_01: Yes.
- 1:47SPEAKER_00: We haven't like newly rescored the model today
- 1:50SPEAKER_00: and nothing we discuss here is personal trade instruction for your portfolio.
- 1:54SPEAKER_00: We're just reverse engineering this research
- 1:56SPEAKER_00: to understand exactly what real world mechanisms have to turn that strong buy
- 2:02SPEAKER_00: into reality.
- 2:03SPEAKER_01: Exactly.
- 2:04SPEAKER_01: And I mean,
- 2:05SPEAKER_01: to understand the business mechanisms,
- 2:07SPEAKER_01: we first need to look at what they actually sell.
- 2:09SPEAKER_01: For anyone outside the medical device sector,
- 2:11SPEAKER_01: Boston Scientific provides a The physical hardware for hospitals and doctors.
- 2:16SPEAKER_01: We're looking at treatments for abnormal heart rhythms, vascular disease, chronic pain.
- 2:21SPEAKER_01: The cardiovascular side alone makes up roughly two-thirds of their total sales.
- 2:25SPEAKER_00: Okay,
- 2:25SPEAKER_00: let's ground this in the flagship technology driving those cardiovascular sales
- 2:29SPEAKER_00: because the research heavily scrutinizes Ferrapulse and Watchman.
- 2:34SPEAKER_00: Instead of just dropping those names, let's break down the mechanics a bit.
- 2:37SPEAKER_00: How does Ferrapulse actually work on a patient?
- 2:40SPEAKER_01: So, Feripulse is a system that delivers pulsed electric fields via a catheter.
- 2:46SPEAKER_01: It's meant for eligible patients dealing with atrial fibrillation.
- 2:48SPEAKER_00: Okay.
- 2:49SPEAKER_00: The irregular heartbeat.
- 2:50SPEAKER_01: Right.
- 2:51SPEAKER_01: And historically,
- 2:51SPEAKER_01: treating this involved using extreme heat or cold
- 2:54SPEAKER_01: to intentionally scar heart tissue, which blocks the abnormal electrical signals.
- 2:59SPEAKER_01: But Feripulse uses incredibly fast electrical pulses to achieve that same tissue targeting.
- 3:04SPEAKER_00: Wow.
- 3:05SPEAKER_00: Okay.
- 3:06SPEAKER_00: And then you have Watchman, which tackles a different part of the atrial fibrillation problem.
- 3:11SPEAKER_00: I always picture it as, well, like a tiny parachute-like device.
- 3:15SPEAKER_01: That is a very accurate visual, actually.
- 3:18SPEAKER_01: The Watchman device physically closes off the left atrial appendage in the heart.
- 3:22SPEAKER_00: And the goal there is just to stop clots.
- 3:25SPEAKER_01: Yeah.
- 3:25SPEAKER_01: The entire goal is to reduce the risk of blood clots escaping from
- 3:28SPEAKER_01: that specific appendage, which could travel and cause a stroke in suitable patients.
- 3:32SPEAKER_00: Right.
- 3:33SPEAKER_00: But here's where I want to draw a very hard line though.
- 3:36SPEAKER_00: It is dangerously easy to fall into the trap of telling like a binary patient success story.
- 3:42SPEAKER_00: We can't look at Watchmen and pretend it magically treats
- 3:44SPEAKER_00: the underlying electrical rhythm problem.
- 3:46SPEAKER_00: It just manages one specific stroke risk.
- 3:49SPEAKER_01: That distinction is vital.
- 3:51SPEAKER_01: We cannot invent a universal perfect safety claim here.
- 3:54SPEAKER_01: These are highly functional medical interventions.
- 3:57SPEAKER_01: They're incredibly useful for humanity,
- 3:59SPEAKER_01: but they are not magic wands
- 4:00SPEAKER_01: and they absolutely do not guarantee flawless clinical outcomes
- 4:03SPEAKER_01: for every single human body.
- 4:04SPEAKER_00: Right.
- 4:06SPEAKER_00: So we have complex technology that isn't a guaranteed perfect cure operating in
- 4:11SPEAKER_00: a highly competitive hospital setting.
- 4:13SPEAKER_00: How does a strong buy rating survive that kind of operational friction?
- 4:18SPEAKER_01: Well...
- 4:19SPEAKER_01: You have to look at the money.
- 4:21SPEAKER_00: Let's pivot to the hard numbers from their Q2 report, which ended June 30.
- 4:26SPEAKER_00: Their quarterly sales were about $5.4 billion.
- 4:30SPEAKER_00: That's growing roughly 7.5% on a reported basis and 7% organically.
- 4:36SPEAKER_01: Which sales growth is a great headline, right?
- 4:38SPEAKER_01: But the real test is the cash bridge.
- 4:41SPEAKER_01: If you look at the first half of the year, their operating cash was about $1.8 billion.
- 4:46SPEAKER_01: But a company like this requires immense upkeep.
- 4:49SPEAKER_01: So you have to subtract roughly $370 million for physical equipment
- 4:54SPEAKER_01: and internal software purchases.
- 4:56SPEAKER_01: When you do that math, you are left with roughly $1.5 billion.
- 4:59SPEAKER_01: Roughly $1.5 billion.
- 5:03SPEAKER_00: Which sounds like a lot of money until you realize that that's the cash remaining
- 5:07SPEAKER_00: before they even touch acquisitions or debt financing.
- 5:11SPEAKER_01: And that is the crux of the issue.
- 5:13SPEAKER_01: That one and a half billion is just a period cash flow measure.
- 5:17SPEAKER_01: It's not a static pile of gold in a vault.
- 5:19SPEAKER_01: And it certainly isn't a recurring six month promise.
- 5:22SPEAKER_01: Plus,
- 5:23SPEAKER_01: standard accounting doesn't neatly separate that equipment and software spending
- 5:26SPEAKER_01: into routine maintenance versus new growth investment.
- 5:29SPEAKER_01: It all just comes out of the same pot.
- 5:31SPEAKER_00: Even their margins tell a story of operational drag.
- 5:34SPEAKER_00: I mean, their GAAP operating margins were about 22%, compared to roughly 28% when adjusted.
- 5:41SPEAKER_00: And that lower GAAP result actually had a tailwind.
- 5:44SPEAKER_00: It was helped by an $83 million tariff recovery.
- 5:47SPEAKER_01: Yeah, which they responsibly pulled out of the adjusted bridge.
- 5:50SPEAKER_00: Right.
- 5:51SPEAKER_00: It really reminds me of our earlier Intuit conversation.
- 5:55SPEAKER_00: Intuit is obviously a totally different software business,
- 5:57SPEAKER_00: but we asked the exact same fundamental question.
- 6:01SPEAKER_00: Like, how much actual cash remains for shareholders after
- 6:04SPEAKER_00: a company makes these incredibly heavy growth and operational investments?
- 6:09SPEAKER_01: Adjusted earnings simply do not pay the bills.
- 6:11SPEAKER_01: Product mix,
- 6:12SPEAKER_01: intense hospital procurement pushback,
- 6:14SPEAKER_01: and heavy operational costs all drag on that final cash number.
- 6:18SPEAKER_00: So let's talk about the weight of their debt,
- 6:21SPEAKER_00: because this is where the financial picture gets incredibly heavy.
- 6:24SPEAKER_00: As of June 30, they were sitting on roughly $540 million in cash.
- 6:28SPEAKER_00: But stacked against that is about $12.6 billion in carrying debt.
- 6:33SPEAKER_01: Yeah, it's massive.
- 6:35SPEAKER_00: That leaves them operating with roughly $12.1 billion in net debt.
- 6:39SPEAKER_00: And hovering over all of this is the impending Penumbra acquisition.
- 6:43SPEAKER_01: Penumbra is the massive shadow over this entire thesis.
- 6:47SPEAKER_01: The deal is still pending with an announced enterprise value of about 14.5 billion.
- 6:53SPEAKER_01: And the proposed cash consideration is roughly 11 billion.
- 6:56SPEAKER_01: But the critical mechanism to understand here is
- 6:58SPEAKER_01: that this 11 billion will be funded using existing cash plus new debt.
- 7:04SPEAKER_00: So they haven't even borrowed the money yet.
- 7:06SPEAKER_00: It's like planning to buy a mansion on a new credit card
- 7:09SPEAKER_00: while you're already drowning in mortgage payments.
- 7:11SPEAKER_00: And none of Boston Scientific's current revenue today includes Penumbra because
- 7:15SPEAKER_00: the acquisition isn't complete.
- 7:17SPEAKER_01: Exactly.
- 7:18SPEAKER_01: The capital allocation is just aggressive.
- 7:22SPEAKER_01: Physical equipment is just one drain.
- 7:24SPEAKER_01: In the first half alone, they expensed about $1.1 billion in R&D.
- 7:28SPEAKER_00: Just in the first half?
- 7:29SPEAKER_01: Yes.
- 7:30SPEAKER_01: On top of that, they made a 1.5 billion minority investment plus an option in Myronis.
- 7:36SPEAKER_01: And that wasn't even buying the entire valve business.
- 7:39SPEAKER_01: You know, that was a 1.5 billion dollar foot in the door.
- 7:42SPEAKER_00: And then the real world throws a massive wrench into the gears because
- 7:47SPEAKER_00: on August 25th, they suffered a cyber incident.
- 7:50SPEAKER_00: It disrupted their own manufacturing, their order processing, shipping.
- 7:54SPEAKER_01: Right.
- 7:54SPEAKER_01: And the fallout from that disruption led directly to their September 8 downside warning.
- 7:59SPEAKER_01: They had to explicitly state that achieving their July ranges for both Q3
- 8:03SPEAKER_01: and full year sales growth and adjusted EPS targets is now unlikely.
- 8:08SPEAKER_00: And they gave absolutely zero replacement numerical ranges?
- 8:11SPEAKER_01: None.
- 8:12SPEAKER_00: They basically threw their hands up and said,
- 8:13SPEAKER_00: we can't hit the old targets and we don't know what the new targets are yet.
- 8:17SPEAKER_01: Because restoring computer systems
- 8:19SPEAKER_01: on September 9th does not instantly recover lost sales
- 8:22SPEAKER_01: or repair your financial guidance.
- 8:24SPEAKER_01: Their September 22 investigation findings were strictly limited to the stated scope
- 8:28SPEAKER_01: of the IT breach, not the long-term financial damage.
- 8:31SPEAKER_00: Right.
- 8:32SPEAKER_00: So given a cyber warning with no new guidance,
- 8:36SPEAKER_00: massive pending acquisition debts,
- 8:39SPEAKER_00: and billions in R&D, how is the market digesting all of this?
- 8:44SPEAKER_00: Let's look at the actual stock price to anchor the model scenarios.
- 8:47SPEAKER_01: Yeah, for a reference point, the October 19 IEX trade price was roughly $44.
- 8:53SPEAKER_01: Based on that exact price entry point, the AI research outlines a few fixed-date scenarios.
- 8:58SPEAKER_01: But keep in mind, these are distinct aggregations.
- 9:00SPEAKER_01: They aren't calibrated probabilities.
- 9:02SPEAKER_01: And they are cumulative returns leading up to those fixed 2027 and 2031 dates.
- 9:08SPEAKER_00: Okay, so they aren't annualized percentages.
- 9:10SPEAKER_00: Correct.
- 9:11SPEAKER_00: Walk me through the evidence-weighted base case first.
- 9:13SPEAKER_00: If they navigate this reasonably well, what does the model see?
- 9:17SPEAKER_01: The base case projects roughly 19% price appreciation on the short end and 119% on
- 9:23SPEAKER_01: the long end.
- 9:24SPEAKER_00: Okay, that implies they successfully absorbed the cyber hit and managed the debt.
- 9:29SPEAKER_00: What if everything goes perfectly?
- 9:31SPEAKER_01: The separate simple average bull case models roughly 30% on the short end and 177%
- 9:37SPEAKER_01: on the long end.
- 9:38SPEAKER_01: But we also have to examine the separate simple average bear case,
- 9:42SPEAKER_01: which models roughly 3.8% on the short end and 67% on the long end.
- 9:47SPEAKER_00: I have to pause on that bear case.
- 9:49SPEAKER_00: A 67% gain over a few years in a bear scenario sounds suspiciously optimistic.
- 9:55SPEAKER_00: If I tell you that your worst case scenario is making a 67% return,
- 9:58SPEAKER_00: you're going to think I'm selling you snake oil.
- 10:01SPEAKER_01: And that is a crucial call out.
- 10:02SPEAKER_01: A modeled bear scenario is not an absolute catastrophic floor.
- 10:06SPEAKER_01: Reality can always get much worse.
- 10:08SPEAKER_01: The bear scenario here simply reflects sustained competitive pressure
- 10:12SPEAKER_01: and weaker cash conversion.
- 10:13SPEAKER_01: It doesn't model the company going bankrupt or a total failure of their product lines.
- 10:17SPEAKER_00: Right.
- 10:18SPEAKER_00: And it's worth noting to the listener that there is no safety net while you wait
- 10:22SPEAKER_00: to find out which scenario plays out.
- 10:24SPEAKER_00: Boston Scientific pays zero ordinary cash dividend.
- 10:28SPEAKER_01: Yep.
- 10:28SPEAKER_00: Annual, short end, long end.
- 10:30SPEAKER_00: It is zero dividend cash across the board.
- 10:34SPEAKER_00: If the stock stalls out at that $44 mark,
- 10:36SPEAKER_00: there is no dividend uplift to bail out your portfolio.
- 10:39SPEAKER_01: You are relying entirely on the company's ability to drive the appreciation of the asset itself.
- 10:45SPEAKER_00: So let's map out the real world forces dictating whether we hit that 119% base case
- 10:51SPEAKER_00: or sink toward the bear case.
- 10:53SPEAKER_00: It feels like a massive tug of war.
- 10:55SPEAKER_01: Well, on the driver's side, you have the undeniable broad demand for cardiovascular procedures.
- 11:00SPEAKER_01: You have genuine, useful innovation reaching eligible patients.
- 11:05SPEAKER_01: You have the restoration of their distribution channels post cyber attack.
- 11:08SPEAKER_01: And they're attempting to unlock conditional operating efficiencies.
- 11:12SPEAKER_00: But the frictions pulling in the opposite direction are incredibly heavy.
- 11:15SPEAKER_00: I mean, they are facing rival ablation platforms that directly challenge ferrapulse.
- 11:20SPEAKER_00: They have hospital procurement teams fighting them tooth and nail on pricing.
- 11:24SPEAKER_00: Plus, You know,
- 11:25SPEAKER_00: the massive financing and integration demands of a number that we just outlined.
- 11:29SPEAKER_01: And the geographical split on those frictions is really telling.
- 11:32SPEAKER_01: Look at Q2 electrophysiology sales, which came in at about nine hundred and twenty million.
- 11:38SPEAKER_01: The U.S.
- 11:38SPEAKER_01: organic growth for that division was an anemic three percent,
- 11:42SPEAKER_01: while internationally it was growing at twenty three percent.
- 11:44SPEAKER_00: That's a huge gap.
- 11:45SPEAKER_01: Yeah.
- 11:46SPEAKER_01: Furthermore,
- 11:47SPEAKER_01: Watchmen sales were about five hundred and ten million
- 11:50SPEAKER_01: and they are facing slower referrals for
- 11:52SPEAKER_01: that left atrial appendage closure procedure.
- 11:55SPEAKER_00: We cover the normal push and pull,
- 11:57SPEAKER_00: but what about the rare tails,
- 11:59SPEAKER_00: like the events that sit completely outside the standard scenarios?
- 12:03SPEAKER_01: The upside tail would require an unexpected,
- 12:06SPEAKER_01: massive clinical or labeling success or unusually strong market uptake
- 12:11SPEAKER_01: that broadens their earnings far beyond the central baseline.
- 12:14SPEAKER_01: The downside tail,
- 12:15SPEAKER_01: conversely,
- 12:16SPEAKER_01: would be a rare,
- 12:17SPEAKER_01: serious safety or regulatory restriction or a completely failed integration of
- 12:22SPEAKER_01: an acquisition.
- 12:23SPEAKER_00: Okay, so outcomes materially worse than the positive numeric bear case we discussed.
- 12:28SPEAKER_00: Well, since we're talking about clinical success as an upside tail,
- 12:32SPEAKER_00: we really need a reality check on Watchmen.
- 12:35SPEAKER_00: The clinical headlines for the Champion AF trial sounded fantastic on the surface.
- 12:39SPEAKER_01: The ditto was genuinely promising.
- 12:41SPEAKER_01: The Watchmen Champion AF trial successfully met its pre-specified non-inferiority
- 12:46SPEAKER_01: margin on the efficacy composite.
- 12:48SPEAKER_01: It also achieved superiority on specified bleeding outcomes compared to standard blood thinners.
- 12:53SPEAKER_00: But showing non-inferiority to a blood thinner in
- 12:55SPEAKER_00: a trial does not mean every hospital in America instantly abandons medication
- 13:00SPEAKER_00: to surgically install your device.
- 13:02SPEAKER_01: No, not at all.
- 13:04SPEAKER_01: Promising first-line persistent AFib results do not automatically hand you FDA
- 13:08SPEAKER_01: approval for first-line use.
- 13:10SPEAKER_01: Clinical evidence is just step one.
- 13:12SPEAKER_01: Regulatory indication is step two, and convincing an insurer to actually pay for the procedure.
- 13:17SPEAKER_00: Is a brutal step three.
- 13:19SPEAKER_01: Exactly.
- 13:19SPEAKER_01: There is no universal stroke protection guarantee that bypasses payer steps.
- 13:23SPEAKER_00: So if the clinical path is that steep and the financial frictions are that heavy,
- 13:28SPEAKER_00: where's the actual hidden market opportunity?
- 13:31SPEAKER_00: Why are these models pointing to a strong buy?
- 13:33SPEAKER_01: The core thesis relies on what the research calls the alpha gap.
- 13:37SPEAKER_01: The hypothesis is that the market is experiencing intense anxiety over these flashy,
- 13:42SPEAKER_01: highly disputed cardiac franchises like the electrophysiology battles.
- 13:46SPEAKER_01: And as a result,
- 13:47SPEAKER_01: investors are discounting Boston Scientific's broader,
- 13:50SPEAKER_01: everyday procedural business too heavily.
- 13:52SPEAKER_00: I love this concept.
- 13:55SPEAKER_00: It's like the market is hyper fixated on a shiny new rocket ship,
- 13:58SPEAKER_00: completely ignoring the fact that the company also owns the mundane,
- 14:02SPEAKER_00: highly profitable supply chain that keeps the entire hospital running.
- 14:05SPEAKER_01: That's exactly the perspective.
- 14:07SPEAKER_01: Essential hospital procedures do not offer unlimited pricing power.
- 14:11SPEAKER_01: And sure, some can be temporarily deferred by patients, but they are incredibly durable.
- 14:16SPEAKER_01: The true test of this alpha gap is whether Boston Scientific can translate
- 14:20SPEAKER_01: that boring durability into per share cash after they survive the competition,
- 14:25SPEAKER_01: fund their massive R&D, and pay the interest on their acquisition debt.
- 14:29SPEAKER_00: This directly mirrors the alphabet deep dive we did earlier this month.
- 14:33SPEAKER_00: Completely different sector, obviously, but we asked the exact same fundamental question.
- 14:37SPEAKER_00: How does a massive technology company take billions of dollars
- 14:40SPEAKER_00: in aggressive investments and successfully convert them into per share cash?
- 14:45SPEAKER_00: A brilliant technological moat is useless to an investor
- 14:48SPEAKER_00: if it requires infinite capital to maintain.
- 14:51SPEAKER_01: Spot on.
- 14:52SPEAKER_01: But not all financial models are convinced Boston Scientific can actually pull this off.
- 14:57SPEAKER_01: September's research contains 14 correlated AI research contributions,
- 15:01SPEAKER_01: with 12 of them sharing one Gemini model version.
- 15:05SPEAKER_00: So what are these distinct models actually debating?
- 15:08SPEAKER_01: The core disagreement hinges on the structural damage of electrophysiology share
- 15:12SPEAKER_01: and pricing erosion.
- 15:14SPEAKER_01: Is the current pressure a permanent structural decline or just a temporary transition period?
- 15:20SPEAKER_01: Further,
- 15:20SPEAKER_01: they're debating
- 15:21SPEAKER_01: whether these aggressive acquisitions will actually earn enough return
- 15:25SPEAKER_01: to justify their enormous cost after accounting for the heavy debt financing.
- 15:29SPEAKER_00: How does that debate split across the different model weightings?
- 15:33SPEAKER_01: The higher weight polymath perspective is highly cautious.
- 15:36SPEAKER_01: It's scrutinizing the clinical evidence,
- 15:38SPEAKER_01: the sluggish cash generation, and the rising leverage very strictly.
- 15:43SPEAKER_01: But the lower weight model expects a smoother re-rating by the market,
- 15:47SPEAKER_01: assuming the company will successfully navigate this turbulence.
- 15:50SPEAKER_00: Okay.
- 15:51SPEAKER_00: So if you are listening to this and wondering when
- 15:54SPEAKER_00: the market will actually validate one side or the other, what is the timeline?
- 15:58SPEAKER_01: The models outline a path of conditional weighted checkpoints.
- 16:03SPEAKER_01: They project roughly 1.6% appreciation by December 2026,
- 16:08SPEAKER_01: then roughly 8% by March 2027,
- 16:11SPEAKER_01: moving up to roughly 14% by June 2027,
- 16:15SPEAKER_01: and finally hitting that roughly 19% base case by September 2027.
- 16:20SPEAKER_00: But those are just theoretical model checkpoints, right?
- 16:23SPEAKER_00: The real world doesn't operate on a smooth curve.
- 16:26SPEAKER_00: What is the next corporate calendar event where management has to face these questions?
- 16:31SPEAKER_01: The next real world test is the Q3 earnings call on October 28.
- 16:36SPEAKER_01: But I need to offer a strong warning regarding this event.
- 16:39SPEAKER_01: This is a planned operational and financial outlook update.
- 16:42SPEAKER_01: It is an opportunity for management to speak,
- 16:45SPEAKER_01: but it is absolutely not a guaranteed event where the company will fully quantify
- 16:49SPEAKER_01: the exact costs of the cyber incident or provide neat new numerical ranges for
- 16:54SPEAKER_01: the year.
- 16:55SPEAKER_00: Yeah,
- 16:55SPEAKER_00: they could easily just say the investigation is ongoing and we are still assessing
- 16:59SPEAKER_00: the financial impact.
- 17:01SPEAKER_00: And let's not forget,
- 17:02SPEAKER_00: they are also shifting to
- 17:03SPEAKER_00: a brand new three segment organizational structure taking effect on January 1, 2027.
- 17:08SPEAKER_00: Q2 reporting was still using the old two segment structure.
- 17:12SPEAKER_00: So tracking their internal performance is about to get significantly more complicated.
- 17:16SPEAKER_01: Exactly.
- 17:17SPEAKER_01: And the narrative surrounding this company is shifting incredibly fast
- 17:21SPEAKER_01: as we approach that October 28 call.
- 17:23SPEAKER_01: To understand the velocity of the shift,
- 17:25SPEAKER_01: you have to compare the July research against the September research.
- 17:29SPEAKER_00: Walk me through the difference.
- 17:30SPEAKER_01: In July, we had 12 research contributions.
- 17:33SPEAKER_01: The overarching ficus was heavily on the defensive nature of their procedure demand
- 17:37SPEAKER_01: and the company's ability to self-fund its operations.
- 17:40SPEAKER_01: It was a narrative of stable, durable demand.
- 17:43SPEAKER_00: Okay.
- 17:44SPEAKER_01: But by September, we had 14 contributions and the focus shifted radically.
- 17:47SPEAKER_01: Suddenly,
- 17:48SPEAKER_01: the models were placing intense scrutiny on electrophysiology competition,
- 17:52SPEAKER_01: the timeline for recovering from the cyber attack and the harsh realities
- 17:56SPEAKER_01: of financing these pending acquisitions.
- 17:58SPEAKER_00: Wait, hold on.
- 17:59SPEAKER_00: You're telling me the narrative shifted from stable demand to harsh execution.
- 18:04SPEAKER_00: But you also just told me the panel size changed from 12 models in July to 14 models
- 18:09SPEAKER_00: in September.
- 18:11SPEAKER_00: Isn't this narrative shift just a mathematical distortion?
- 18:14SPEAKER_00: Like, how do we know the actual business changed rather than just the AI panel method changing?
- 18:19SPEAKER_01: And that is a vital piece of skepticism.
- 18:42SPEAKER_01: The research focus fundamentally had to shift from durable demand
- 18:46SPEAKER_01: to harsh capital allocation execution tests because
- 18:49SPEAKER_01: the business reality demanded it.
- 18:51SPEAKER_00: That makes total sense.
- 18:52SPEAKER_00: The real world intervened and broke the clean, stable model.
- 18:56SPEAKER_00: It strongly recalls episode 24 on Novo Nordisk.
- 19:00SPEAKER_00: Even with completely different pharmaceutical economics,
- 19:03SPEAKER_00: the core thesis challenge remains identical.
- 19:06SPEAKER_00: How does massive patient demand actually become reliable profits in cash?
- 19:11SPEAKER_01: That is the universal challenge.
- 19:13SPEAKER_00: Though we should briefly note it's important
- 19:15SPEAKER_00: to keep pharmaceutical clinical evidence
- 19:17SPEAKER_00: and medical device clinical evidence distinct in your mind.
- 19:20SPEAKER_00: Sure.
- 19:21SPEAKER_00: The regulatory and adoption pathways function quite differently.
- 19:24SPEAKER_00: But the financial finish line, free cash flow, is exactly the same.
- 19:29SPEAKER_01: So if the cash flow doesn't materialize, what proves this entire strong by thesis wrong?
- 19:35SPEAKER_01: What are the metrics of failure that invalidate the models?
- 19:38SPEAKER_00: The invalidation triggers are clear.
- 19:40SPEAKER_01: The thesis breaks if we see persistent electrophysiology share and pricing deterioration.
- 19:45SPEAKER_01: It breaks if they permanently lose hospital customers who defect to competitors
- 19:49SPEAKER_01: because of the cyber disruption.
- 19:51SPEAKER_01: It breaks if they show weak cash conversion or,
- 19:53SPEAKER_01: critically,
- 19:54SPEAKER_01: if the financing costs and integration friction
- 19:56SPEAKER_01: of their pending acquisitions simply overwhelm the acquired growth.
- 20:01SPEAKER_00: You know,
- 20:01SPEAKER_00: one metric I hear thrown around a lot when people look
- 20:03SPEAKER_00: for failure triggers is inventory days.
- 20:08SPEAKER_00: If inventory is piling up,
- 20:09SPEAKER_00: does that mean the business is freezing like a hospital outage or
- 20:12SPEAKER_00: a warehouse freeze?
- 20:14SPEAKER_01: We have to apply an accounting reality check there.
- 20:17SPEAKER_01: Inventory days is an aggregate accounting ratio.
- 20:20SPEAKER_01: It is not a literal reflection of the physical age of every device sitting on a shelf.
- 20:24SPEAKER_01: And it is definitely not proof of a warehouse freeze or global risk rank dropping.
- 20:29SPEAKER_01: Most importantly,
- 20:30SPEAKER_01: mathematically,
- 20:31SPEAKER_01: a late August cyber incident cannot possibly explain
- 20:34SPEAKER_01: a June quarter inventory buildup.
- 20:36SPEAKER_00: Right.
- 20:36SPEAKER_00: They have it in completely different quarters.
- 20:38SPEAKER_01: Exactly.
- 20:39SPEAKER_01: So we can't just isolate one lagging accounting ratio and use it as a mechanical trade trigger.
- 20:44SPEAKER_01: The invalidation of this thesis will be tested over several quarters
- 20:47SPEAKER_01: of hard compounding evidence, not by a single anomalous spreadsheet cell.
- 20:51SPEAKER_00: Well, let's synthesize this.
- 20:53SPEAKER_00: The dated model view for Boston Scientific is a strong buy at both the one-year
- 20:58SPEAKER_00: and five-year horizons.
- 21:00SPEAKER_00: But as we've unpacked today, that positive rating is not a guarantee based on past glory.
- 21:05SPEAKER_00: It hinges entirely on reliable operational delivery,
- 21:10SPEAKER_00: competitive durability in the face of fierce rivals,
- 21:12SPEAKER_00: and the brutal ability to convert medical innovation into actual per-share cash
- 21:18SPEAKER_00: after paying for hefty investments and massive acquisitions.
- 21:21SPEAKER_01: Having incredibly useful medical devices is wonderful for the advancement
- 21:25SPEAKER_01: of human health care,
- 21:27SPEAKER_01: but useful devices alone do not settle the valuation question for an investor.
- 21:32SPEAKER_00: Absolutely.
- 21:33SPEAKER_00: I invite you to inspect the dated Boston scientific research for yourself on the platform.
- 21:38SPEAKER_00: And of course, keep listening, watching and subscribe so you don't miss our upcoming analyses.
- 21:43SPEAKER_01: You definitely won't want to miss the next one.
- 21:45SPEAKER_01: We are covering Northrop Grumman next,
- 21:47SPEAKER_01: where we will tackle how a massive defense order book actually translates
- 21:50SPEAKER_01: into real cash.
- 21:52SPEAKER_00: It seems to be the ultimate theme of the month.
- 21:54SPEAKER_00: I will leave you with this final thought to mull over.
- 21:57SPEAKER_00: In the end,
- 21:58SPEAKER_00: even the most miraculous,
- 22:00SPEAKER_00: life-saving medical devices still have to answer to the simplest,
- 22:04SPEAKER_00: most unforgiving math in the world, cash flow.
- 22:08SPEAKER_00: Thanks for joining us, and we will see you next time.